Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)

NCT05909436 is registered in ClinicalTrials.gov with Guangzhou Gloria Biosciences Co., Ltd. as lead sponsor.

NCT NCT05909436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05909436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2022
Completion date
December 31, 2026
Enrollment
107 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor